Zimmer Biomet Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Zimmer Biomet Holdings, Inc. on September 8, 2026. The report discloses a significant executive departure and related compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and severance terms.
Material Changes
On September 8, 2026, the Company notified Kevin Thornal, Group President of Global Businesses and the Americas, that his position is being restructured. Mr. Thornal will depart effective September 30, 2026.
Management Commentary, Risks, and Unusual Items
Mr. Thornal is eligible for severance benefits under the Company's Restated Executive Severance Plan. The benefits include:
- A lump sum equal to twelve months of his annual base salary plus target annual bonus.
- Twelve months of current monthly COBRA premiums.
Receipt of these benefits is conditioned upon Mr. Thornal executing and not revoking a general release in favor of the Company. The Company issued a press release regarding this matter on September 8, 2026.
Investor Verification Checklist
- Verify the exact terms of the Restated Executive Severance Plan referenced in the April 1, 2026 proxy statement.
- Confirm the status of the general release required for severance payment.
- Review the attached press release (Exhibit 99.1) for additional context on the restructuring.
- Monitor future filings for the appointment of a successor to the Group President role.